Phraxis completes first commercial EndoForce connector case
Phraxis, Inc. has successfully completed the world’s first commercial case using its FDA-approved EndoForceAnastomotic Connector, establishing a pivotal milestone in dialysis vascular access innovation. The groundbreaking procedure, performed at Spartanburg Regional Medical Center in South Carolina, signals the beginning of U.S. commercialisation for this novel endovascular device designed to standardise arteriovenous graft creation.
Revolutionary approach to vascular anastomosis
Dr. Ari Kramer, vascular access surgeon and clinical pioneer of EndoForce™, performed the historic procedure. “Every decision we make in the OR comes back to the patient. With EndoForce, we have a tool designed to make graft-to-vein connections more predictable and efficient,” said Dr. Kramer. “Launching the first commercial case at Spartanburg Regional is a meaningful step forward for our dialysis community.”
The EndoForcesystem represents a paradigm shift from traditional hand-sewn surgical sutures, offering precise, reproducible connections for PTFE grafts. The device enables endovascular anastomosis whilst eliminating the need for surgical dissection of the venous anastomosis, promoting optimal vessel-to-graft alignment and reducing tissue trauma.
Clinical performance demonstrates strong outcomes
The technology’s approval followed extensive clinical validation through a pivotal, multicentre, single-arm study. The device achieved its primary endpoint with a remarkable 92% cumulative patency rate at six months, with secondary endpoints reinforcing its clinical performance credentials.
EndoForceincorporates several proprietary design elements: anchoring barbs that secure the device within the vein, a flexible ePTFE-covered nitinol segment that conforms to vessel walls, and a compressible section that expands within the AVG upon deployment. This configuration supports stable end-to-end anastomosis intended to promote laminar blood flow and reduce turbulent shear stress – critical factors in preventing endothelial buildup and graft failure.
Expanding access to innovative technology
“This achievement is the result of more than a decade of relentless innovation, collaboration with world-class surgeons, and unwavering commitment to patient outcomes,” said Dr. Alex Yevzlin, founder and chief executive officer of Phraxis. “We are proud to see EndoForceenter the clinical arena – where it can make a meaningful difference.”
Geoffrey Beecher, chief commercial officer, emphasised the broader implications: “Today represents more than a first commercial case – it’s the beginning of a new standard in vascular access surgery. Dialysis patients deserve consistent, reliable solutions, and EndoForce is designed to deliver on that promise.”
The Minneapolis-based company plans to expand availability through partnerships with leading vascular surgeons and health systems, with additional clinical sites expected to begin cases in coming months.
- For more information, visit: phraxis.com/endoforce
